A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation
Frithiof, Henrik LU ; Aaltonen, Kristina LU and Rydén, Lisa LU
(2016)
In OncoTargets and Therapy
2016(9).
p.7095-7103
- Abstract
- Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%–15% of primary breast cancer, leading to an activated HER-2 receptor, augmenting growth of cancer cells. Tumor classification is determined in primary tumor tissue and metastatic biopsies. However, malignant cells tend to alter their phenotype during disease progression. Circulating tumor cell (CTC) analysis may serve as an alternative to repeated biopsies. The Food and Drug Administration-approved CellSearch system allows determination of the HER-2 protein, but not of the HER-2 gene. The aim of this study was to optimize a fluorescence in situ hybridization (FISH)-based method to quantitatively determine HER-2 amplification in breast cancer CTCs following CellSearch-based... (More)
- Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%–15% of primary breast cancer, leading to an activated HER-2 receptor, augmenting growth of cancer cells. Tumor classification is determined in primary tumor tissue and metastatic biopsies. However, malignant cells tend to alter their phenotype during disease progression. Circulating tumor cell (CTC) analysis may serve as an alternative to repeated biopsies. The Food and Drug Administration-approved CellSearch system allows determination of the HER-2 protein, but not of the HER-2 gene. The aim of this study was to optimize a fluorescence in situ hybridization (FISH)-based method to quantitatively determine HER-2 amplification in breast cancer CTCs following CellSearch-based isolation and verify the method in patient samples. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/52e3c853-08dc-46cb-b838-0a687803bbfb
- author
- Frithiof, Henrik
LU
; Aaltonen, Kristina
LU
and Rydén, Lisa
LU
- organization
- publishing date
- 2016
- type
- Contribution to journal
- publication status
- published
- subject
- in
- OncoTargets and Therapy
- volume
- 2016
- issue
- 9
- pages
- 7095 - 7103
- publisher
- Dove Medical Press Ltd.
- external identifiers
-
- scopus:84996957449
- wos:000387902600001
- pmid:27895501
- ISSN
- 1178-6930
- DOI
- 10.2147/OTT.S118502
- project
- CTC-MBC, Circulating Tumor Cells in Metastatic Breast Cancer
- Breast Cancer Surgery
- language
- English
- LU publication?
- yes
- id
- 52e3c853-08dc-46cb-b838-0a687803bbfb
- date added to LUP
- 2016-11-29 11:27:39
- date last changed
- 2022-04-24 19:35:54
@article{52e3c853-08dc-46cb-b838-0a687803bbfb,
abstract = {{Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%–15% of primary breast cancer, leading to an activated HER-2 receptor, augmenting growth of cancer cells. Tumor classification is determined in primary tumor tissue and metastatic biopsies. However, malignant cells tend to alter their phenotype during disease progression. Circulating tumor cell (CTC) analysis may serve as an alternative to repeated biopsies. The Food and Drug Administration-approved CellSearch system allows determination of the HER-2 protein, but not of the HER-2 gene. The aim of this study was to optimize a fluorescence in situ hybridization (FISH)-based method to quantitatively determine HER-2 amplification in breast cancer CTCs following CellSearch-based isolation and verify the method in patient samples.}},
author = {{Frithiof, Henrik and Aaltonen, Kristina and Rydén, Lisa}},
issn = {{1178-6930}},
language = {{eng}},
number = {{9}},
pages = {{7095--7103}},
publisher = {{Dove Medical Press Ltd.}},
series = {{OncoTargets and Therapy}},
title = {{A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation}},
url = {{http://dx.doi.org/10.2147/OTT.S118502}},
doi = {{10.2147/OTT.S118502}},
volume = {{2016}},
year = {{2016}},
}